NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Cuprina Holdings (Cayman) Limited (CUPR) Stock Analysis

Cuprina Holdings (Cayman) Limited (CUPR) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CUPR

$2.01

+$0.08 (+4.15%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CUPR with… →

CUPR Key Statistics

As of Oct 21, 2026
Trading
Open
$2.02
Previous Close
$1.93
Day's Range
1.96–2.03
52-Week Range
1.45–14.80
Volume
6.91K
Valuation
Market Cap
$14.08M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
282.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.40
Financials (FY)
Revenue (FY)
$49.89K+3.26%
Net Income (FY)
−$4.67M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.24M
1-Year Return
−73.55%
Dividend and dates
Avg Volume
99.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CUPR closed at $2.01, −73.55% over 1 year.

Cuprina Holdings (Cayman) Limited (CUPR) has a market capitalization of $14.08M.

In fiscal 2025, CUPR reported revenue of $49.89K.

CUPR Stock Return by Calendar Year

Cuprina Holdings (Cayman) Limited (CUPR) return since Apr 2025: what $10,000 became

1 year
$10,000 $2,645
−73.55%
Since Apr 2025
$10,000 $605
−93.95%

If you had invested $10,000 in Cuprina Holdings (Cayman) Limited (CUPR) at the close on April 10, 2025, the earliest close on record here, it would have been worth $605 at the close on October 21, 2026: −93.95% in total, −84.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−37.19%
2025 (partial year)−90.36%

As of October 21, 2026.

CUPR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$49.89K−$4.67M−9,366.8%
2024$48.32K−$1.56M−3,229.5%
2023$100.77K−$1.12M−1,111.0%
2022$56.60K−$1.09M−1,933.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$49.89K−$645.00−$4.57M−$4.67M−9,366.8%
2024$48.32K−$3.02K−$1.48M−$1.56M−3,229.5%
2023$100.77K$36.61K−$1.03M−$1.12M−1,111.0%
2022$56.60K$19.98K−$1.12M−$1.09M−1,933.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CUPR Valuation vs Medical Instruments & Supplies Median

Median of 50 stocks
MetricCUPRMedical Instruments & Supplies medianvs median
P/S ratio282.152.60108.6x the median

Medians across 50 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cuprina Holdings (Cayman) Limited (CUPR) is capitalised at $14.08M on the latest close. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 10.

Over the past 52 weeks the price has ranged from $1.45 to $14.80. CUPR last closed at $2.01 on October 21, 2026. That is +$0.08 (+4.15%) against the previous close. The latest close sits 39.1% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $49.89K. Against the prior fiscal year total of $48.32K, that is a change of +3.26%. The same year closed with a net loss of $4.67M. Earnings per share on a trailing basis come to −1.4.

Across the 4 fiscal years on file, revenue moves from $56.60K in 2022 to $49.89K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 282.15. On price-to-sales that is 108.6 times the Medical Instruments & Supplies median of 2.6. 50 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 1 year is 205.48%. Over the trailing twelve months the total return is −73.55%. The stored price history starts on April 10, 2025, and the total return since then is −93.95%.

Growth & Income

No dividend is on file for CUPR.

2026 is still running; the total return is −37.19% year to date.

Peer Comparison

Cuprina Holdings (Cayman) Limited (CUPR) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cuprina Holdings (Cayman) Limited CUPR $14.08M —
Intuitive Surgical, Inc. ISRG $151.25B 51.8
Becton, Dickinson and Company BDX $52.79B 45.1
Medline Inc. MDLN $47.51B 88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. Cuprina Holdings (Cayman) Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

 BDX

Becton, Dickinson and Company

$52.79B

 MDLN

Medline Inc.

$47.51B

 RMD

ResMed Inc.

$34.63B

 ALC

Alcon Inc.

$32.60B

 WST

West Pharmaceutical Services, Inc.

$27.69B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cuprina Holdings (Cayman) Limited

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.

Visit website →